Travoprost ER is under clinical development by Ocular Therapeutix and currently in Phase II for Ocular Hypertension. According to GlobalData, Phase II drugs for Ocular Hypertension have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Travoprost ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Travoprost ER overview

Travoprost extended release (ER) is under development for the treatment of open-angle glaucoma and ocular hypertension. The drug candidate is a bioresorbable extended release travoprost implant delivered via a fine-gauge needle injection through intracameral route intended to deliver drug for up to four to six months. Travoprost is a synthetic prostaglandin F2a analogue which acts by targeting prostaglandin F2 alpha receptor (PTGFR). The drug candidate is developed based on hydrogel platform technology.

Ocular Therapeutix overview

Ocular Therapeutix is a biopharmaceutical company that discovers, develops and commercializes therapies for treating eye diseases. The company’s lead product candidate DEXTENZA is used for the treatment of post-surgical Ocular inflammation and pain. Its pipeline products include OTX-TP, used for treating glaucoma and Ocular hypertension, OTX-BPI, targeting acute Ocular pain, OTX-BDI, against post-op pain, inflammation and anti-bacterial infections; OTX-KTO for treating allergic conjunctivitis; OTX-CSI, against dry eye. Ocular Therapeutix also develops intracameral implants for treating multiple eye disorders. The company works in collaboration with Regeneron Pharmaceuticals Inc to develop formulations for the treatment of wet AMD and other serious retinal diseases. Ocular Therapeutix is headquartered in Bedford, Massachusetts, the US.

For a complete picture of Travoprost ER’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.